{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:10:36Z","timestamp":1778037036616,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04761-5","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:54:49Z","timestamp":1774616089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of same-day bilateral intravitreal dexamethasone implantation for diabetic and uveitic macular edema: a single-center experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Is\u0131l Kefeli","family":"Kircali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-0079","authenticated-orcid":false,"given":"Omer","family":"Karti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziya","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan Asli","family":"Utine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Osman","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"6","key":"4761_CR1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1080\/09273948.2016.1184284","volume":"25","author":"JM Fassbender Adeniran","year":"2017","unstructured":"Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and Rare Ocular Side-effects of the Dexamethasone Implant. Ocul Immunol Inflamm. 2017;25(6):834\u201340. https:\/\/doi.org\/10.1080\/09273948.2016.1184284.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"4761_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","volume":"29","author":"JA Haller","year":"2009","unstructured":"Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29(1):46\u201351. https:\/\/doi.org\/10.1097\/IAE.0b013e318188c814.","journal-title":"Retina"},{"issue":"3","key":"4761_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archopht.125.3.309","volume":"125","author":"BD Kuppermann","year":"2007","unstructured":"Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309\u201317. https:\/\/doi.org\/10.1001\/archopht.125.3.309.","journal-title":"Arch Ophthalmol"},{"key":"4761_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12886-015-0106-z","volume":"15","author":"PU Dugel","year":"2015","unstructured":"Dugel PU, Capone A Jr, Singer MA, Dreyer RF, Dodwell DG, Roth DB, SHASTA Study Group, et al. Two or more dexamethasone intravitreal implants in treatment-naive patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol. 2015;15:118. https:\/\/doi.org\/10.1186\/s12886-015-0106-z.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"4761_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4155\/tde-2019-0024","volume":"10","author":"H Massa","year":"2019","unstructured":"Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv. 2019;10(6):343\u201351. https:\/\/doi.org\/10.4155\/tde-2019-0024.","journal-title":"Ther Deliv"},{"issue":"8","key":"4761_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4239\/wjd.v12.i8.1220","volume":"12","author":"O Karti","year":"2021","unstructured":"Karti O, Saatci AO. Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes. 2021;12(8):1220\u201332. https:\/\/doi.org\/10.4239\/wjd.v12.i8.1220.","journal-title":"World J Diabetes"},{"issue":"1","key":"4761_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80\u20136. https:\/\/doi.org\/10.1167\/iovs.10-5285.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4761_CR8","doi-asserted-by":"publisher","unstructured":"Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Ozurdex MEAD, et al. Study. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Group. Ophthalmology. 2014;121(10):1904-14. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024.","DOI":"10.1016\/j.ophtha.2014.04.024"},{"issue":"5","key":"4761_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545\u201353. https:\/\/doi.org\/10.1001\/archophthalmol.2010.339.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"4761_CR10","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Ozurdex GENEVA, Study Group, Li J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.014.","journal-title":"Ophthalmology"},{"issue":"4","key":"4761_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/mi.2023.99","volume":"3","author":"S Koksaldi","year":"2023","unstructured":"Koksaldi S, Kayaba\u015fi M, Ayhan Z, Kaya M, \u00d6zt\u00fcrk T, Yaman A, et al. Dexamethasone intravitreal implant for macular edema and some other rare indications in uveitis. Med Int (Lond). 2023;3(4):39. https:\/\/doi.org\/10.3892\/mi.2023.99.","journal-title":"Med Int (Lond)"},{"issue":"2","key":"4761_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4103\/ijo.IJO_684_21","volume":"70","author":"VD Sweta","year":"2022","unstructured":"Sweta VD, Shibi Dev BN, Sandhya R. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study. Indian J Ophthalmol. 2022;70(2):585\u20139. https:\/\/doi.org\/10.4103\/ijo.IJO_684_21.","journal-title":"Indian J Ophthalmol"},{"key":"4761_CR13","doi-asserted-by":"publisher","unstructured":"Kapoor KG, Colchao JB. Safety of consecut\u0131ve same-day bilateral intravitreal dexamethasone implant (Ozurdex). Retin Cases Brief Rep. 2020;14(2):200\u20132. https:\/\/doi.org\/10.1097\/ICB.0000000000000653.","DOI":"10.1097\/ICB.0000000000000653"},{"key":"4761_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2147\/OPTH.S148990","volume":"12","author":"S Bahadorani","year":"2018","unstructured":"Bahadorani S, Krambeer C, Wannamaker K, Tie W, Jansen M, Espitia J, et al. The effects of repeated Ozurdex injections on ocular hypertension. Clin Ophthalmol. 2018;12:639\u201342. https:\/\/doi.org\/10.2147\/OPTH.S148990.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"4761_CR15","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.18240\/ijo.2020.10.16","volume":"13","author":"N Celik","year":"2020","unstructured":"Celik N, Khoramnia R, Auffarth GU, Sel S, Mayer CS. Complications of dexamethasone implants: risk factors, prevention, and clinical management. Int J Ophthalmol. 2020;13(10):1612\u201320. https:\/\/doi.org\/10.18240\/ijo.2020.10.16.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"4761_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","volume":"104","author":"B Rajesh","year":"2020","unstructured":"Rajesh B, Zarranz-Ventura J, Fung AT, Busch C, Sahoo NK, Rodriguez-Valdes PJ, for International Ozurdex Study Group, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39\u201346. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-313991.","journal-title":"Br J Ophthalmol"},{"key":"4761_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","volume":"128","author":"JA Haller","year":"2010","unstructured":"Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289\u201396. https:\/\/doi.org\/10.1001\/archophthalmol.2010.21.","journal-title":"Arch Ophthalmol"},{"key":"4761_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","volume":"31","author":"DS Boyer","year":"2011","unstructured":"Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915\u201323. https:\/\/doi.org\/10.1097\/IAE.0b013e318206d18c.","journal-title":"Retina"},{"key":"4761_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","volume":"120","author":"DG Callanan","year":"2013","unstructured":"Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843\u201351. https:\/\/doi.org\/10.1016\/j.ophtha.2013.02.018.","journal-title":"Ophthalmology"},{"key":"4761_CR20","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473\u201381. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.002.","journal-title":"Ophthalmology"},{"key":"4761_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jfo.2014.03.001","volume":"37","author":"S Guigou","year":"2014","unstructured":"Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al. Multicenter Ozurdex\u00ae assessment for diabetic macular edema: MOZART study. J Fr Ophtalmol. 2014;37:480\u20135. https:\/\/doi.org\/10.1016\/j.jfo.2014.03.001.","journal-title":"J Fr Ophtalmol"},{"key":"4761_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3928\/23258160-20180601-07","volume":"49","author":"MA Singer","year":"2018","unstructured":"Singer MA, Dugel PU, Fine HF, Capone A Jr, Maltman J. Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study. Ophthalmic Surg Lasers Imaging Retina. 2018;49:425\u201335. https:\/\/doi.org\/10.3928\/23258160-20180601-07.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4761_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000492132","volume":"241","author":"P Mello Filho","year":"2019","unstructured":"Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A, et al. Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. Ophthalmologica. 2019;241:9\u201316. https:\/\/doi.org\/10.1159\/000492132.","journal-title":"Ophthalmologica"},{"key":"4761_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/IAE.0000000000001234","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Agard \u00c9, Vi\u00e9 AL, Bellocq D, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: The Reldex Study. Retina. 2017;37:753\u201360. https:\/\/doi.org\/10.1097\/IAE.0000000000001234.","journal-title":"Retina"},{"key":"4761_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","volume":"127","author":"A Rosenblatt","year":"2020","unstructured":"Rosenblatt A, Udaondo P, Cunha-Vaz J, Sivaprasad S, Bandello F, Lanzetta P, et al. ARTES Study Group. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology. 2020;127:377\u201393. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.005.","journal-title":"Ophthalmology"},{"issue":"3\u20134","key":"4761_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000532056","volume":"246","author":"TC Lin","year":"2023","unstructured":"Lin TC, Tseng PC, Hsu TK, Huang HW, Huang YM, Lo WJ, et al. Same-Day Bilateral Intravitreal Dexamethasone Implants for the Treatment of Diabetic Macular Edema. Ophthalmologica. 2023;246(3\u20134):238\u201344. https:\/\/doi.org\/10.1159\/000532056.","journal-title":"Ophthalmologica"},{"key":"4761_CR27","doi-asserted-by":"publisher","unstructured":"Pleyer U, Klamann M, Laurent TJ, M\u00e4nz M, Hazirolan D, Winterhalter S, et al. Fast and successful management of intraocular inflammation with a single intravitreal dexamethasone implant. Ophthalmologica. 2014;21. https:\/\/doi.org\/10.1159\/000368987.","DOI":"10.1159\/000368987"},{"key":"4761_CR28","doi-asserted-by":"publisher","unstructured":"Querques G, Figus M, De Bernardo M, Toro MD, Gharbiya M, Gallinaro V, et al. Safety profile of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. Ophthalmologica. 2025;12:1\u201318. https:\/\/doi.org\/10.1159\/000545987.","DOI":"10.1159\/000545987"},{"issue":"11","key":"4761_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3928\/23258160-20221018-04","volume":"53","author":"RH Dinh","year":"2022","unstructured":"Dinh RH, Moushmoush O, Kolyvas P, Jacobsen BA, Mathai M, Sanghavi K, et al. Describing Adverse Events Associated with Bilateral Same-Day Intravitreal Dexamethasone Implants. Ophthalmic Surg Lasers Imaging Retina. 2022;53(11):612\u20138. https:\/\/doi.org\/10.3928\/23258160-20221018-04.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4761_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37845\/ret.vit.2023.32.8","volume":"32","author":"K Kasal","year":"2023","unstructured":"Kasal K, Canli MK, Karahan E. The Effect of Topical Antibiotic Use on the Incidence of Endophthalmitis after Intravitreal Injection. J Ret-Vit. 2023;32:46\u201351. https:\/\/doi.org\/10.37845\/ret.vit.2023.32.8.","journal-title":"J Ret-Vit"},{"issue":"10","key":"4761_CR31","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3390\/pharmaceutics14102133","volume":"14","author":"F Baudin","year":"2022","unstructured":"Baudin F, Benzenine E, Mariet AS, Ghezala IB, Bron AM, Daien V, Gabrielle PH, Quantin C, Creuzot-Garcher C. Topical Antibiotic Prophylaxis and Intravitreal Injections: Impact on the Incidence of Acute Endophthalmitis-A Nationwide Study in France from 2009 to 2018. Pharmaceutics. 2022;14(10):2133. https:\/\/doi.org\/10.3390\/pharmaceutics14102133. PMID: 36297568; PMCID: PMC9611403.","journal-title":"Pharmaceutics"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04761-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:13:14Z","timestamp":1778033594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04761-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4761"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04761-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the tenets of the Declaration of Helsinki and was approved by the Non-Interventional Clinical Research Ethics Committee of Dokuz Eyl\u00fcl University (Registration number: 2024\/06\u2009\u2212\u200901). Because of the retrospective design of the study, the requirement for informed consent was waived by the Ethics Committee. All patients\u2019 personal data were protected and handled in compliance with confidentiality standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}